DOP2010000185A - Antagonistas del receptor mineralcorticoide - Google Patents

Antagonistas del receptor mineralcorticoide

Info

Publication number
DOP2010000185A
DOP2010000185A DO2010000185A DO2010000185A DOP2010000185A DO P2010000185 A DOP2010000185 A DO P2010000185A DO 2010000185 A DO2010000185 A DO 2010000185A DO 2010000185 A DO2010000185 A DO 2010000185A DO P2010000185 A DOP2010000185 A DO P2010000185A
Authority
DO
Dominican Republic
Prior art keywords
formula
compound
mineralcorticoid
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
DO2010000185A
Other languages
English (en)
Spanish (es)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000185(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2010000185A publication Critical patent/DOP2010000185A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DO2010000185A 2007-12-19 2010-06-17 Antagonistas del receptor mineralcorticoide DOP2010000185A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19

Publications (1)

Publication Number Publication Date
DOP2010000185A true DOP2010000185A (es) 2010-09-15

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000185A DOP2010000185A (es) 2007-12-19 2010-06-17 Antagonistas del receptor mineralcorticoide

Country Status (33)

Country Link
US (1) US7994164B2 (https=)
EP (2) EP2235007B1 (https=)
JP (1) JP5562866B2 (https=)
KR (1) KR101254382B1 (https=)
CN (1) CN101903377B (https=)
AR (1) AR069554A1 (https=)
AU (1) AU2008343524B2 (https=)
BR (1) BRPI0820805A2 (https=)
CA (1) CA2710409C (https=)
CL (1) CL2008003600A1 (https=)
CO (1) CO6300953A2 (https=)
DK (1) DK2235007T3 (https=)
DO (1) DOP2010000185A (https=)
EA (1) EA017668B1 (https=)
EC (2) ECSP10010266A (https=)
ES (2) ES2396605T3 (https=)
GT (1) GT201000179A (https=)
HR (1) HRP20120916T1 (https=)
IL (1) IL206353A (https=)
MA (1) MA31910B1 (https=)
MX (1) MX2010006911A (https=)
MY (1) MY150474A (https=)
NZ (1) NZ586300A (https=)
PE (1) PE20091057A1 (https=)
PL (1) PL2235007T3 (https=)
PT (1) PT2235007E (https=)
RS (1) RS52594B (https=)
SI (1) SI2235007T1 (https=)
TN (1) TN2010000292A1 (https=)
TW (1) TWI431010B (https=)
UA (1) UA100131C2 (https=)
WO (1) WO2009085584A1 (https=)
ZA (1) ZA201004257B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
WO2010104721A1 (en) * 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
EA027936B1 (ru) 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
EP3160948B1 (en) 2014-06-30 2018-10-24 Astrazeneca AB Benzoxazinone amides as mineralocorticoid receptor modulators
NZ730759A (en) * 2014-11-21 2018-10-26 Lilly Co Eli 1,2-benzothiazole compounds for the treatment of kidney disorders
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CR20240015A (es) * 2016-09-24 2024-04-05 Novo Nordisk As COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)
JP7697961B2 (ja) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
CN1911930A (zh) * 2001-11-21 2007-02-14 千禧药品公司 趋化因子受体拮抗剂及其方法和用途
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
US7482344B2 (en) 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
US20090054417A1 (en) * 2004-07-28 2009-02-26 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
ES2547724T3 (es) 2004-11-10 2015-10-08 Incyte Corporation Compuestos de lactama y su uso como productos farmacéuticos
DK2089367T3 (da) 2006-10-31 2012-02-06 Pfizer Prod Inc Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
EP2142194A1 (en) 2007-03-29 2010-01-13 N.V. Organon Mineralocorticoid receptor antagonists
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP2252615A1 (en) 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
MA31910B1 (fr) 2010-12-01
JP5562866B2 (ja) 2014-07-30
IL206353A (en) 2014-06-30
ECSP12012048A (es) 2012-08-31
EP2537845B1 (en) 2014-03-19
DK2235007T3 (da) 2012-12-17
KR101254382B1 (ko) 2013-04-15
AU2008343524B2 (en) 2012-03-08
EP2235007A1 (en) 2010-10-06
AR069554A1 (es) 2010-02-03
MX2010006911A (es) 2010-10-05
MY150474A (en) 2014-01-30
PL2235007T3 (pl) 2013-03-29
CO6300953A2 (es) 2011-07-21
SI2235007T1 (sl) 2013-01-31
CL2008003600A1 (es) 2010-02-19
JP2011507868A (ja) 2011-03-10
EA017668B1 (ru) 2013-02-28
TW200930721A (en) 2009-07-16
CA2710409C (en) 2012-11-06
KR20100082866A (ko) 2010-07-20
WO2009085584A1 (en) 2009-07-09
NZ586300A (en) 2012-06-29
HK1144284A1 (en) 2011-02-11
EP2537845A1 (en) 2012-12-26
IL206353A0 (en) 2010-12-30
ES2459318T3 (es) 2014-05-09
ECSP10010266A (es) 2010-07-30
HRP20120916T1 (hr) 2012-12-31
TWI431010B (zh) 2014-03-21
EP2235007B1 (en) 2012-10-31
ZA201004257B (en) 2011-11-30
AU2008343524A1 (en) 2009-07-09
CA2710409A1 (en) 2009-07-09
US7994164B2 (en) 2011-08-09
RS52594B (sr) 2013-04-30
CN101903377A (zh) 2010-12-01
TN2010000292A1 (en) 2011-11-11
PE20091057A1 (es) 2009-07-20
BRPI0820805A2 (pt) 2015-06-16
EA201070762A1 (ru) 2010-12-30
GT201000179A (es) 2012-04-16
CN101903377B (zh) 2014-07-09
PT2235007E (pt) 2013-01-22
UA100131C2 (uk) 2012-11-26
ES2396605T3 (es) 2013-02-22
US20090163472A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
DOP2010000185A (es) Antagonistas del receptor mineralcorticoide
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CL2011002989A1 (es) Compuestos heterociclicos inhibidores de la endopeptidasa neutra (nep); composicion farmaceutica; combinacion farmaceutica; uso del compuesto patra tratar un trastorno o enfermedad tal como hipertencion, insuficiencia cardiaca, insuficiencia renal, epilepsia, sindrome metabolico, entre otros.
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
MX336881B (es) Compuestos heterociclicos triciclicos.
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
UY32062A (es) Inhibidores de beta-secretasa
WO2009054423A1 (ja) オキサジアゾリジンジオン化合物
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
ATE530524T1 (de) Substituierte sulfonamid-derivate
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
CR20210085A (es) Compuestos de 2,6-diaminopiridina
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
WO2007146900A3 (en) Antihypertensive therapy method
CO2021016870A2 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
DK1957484T3 (da) Glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
EA201171125A1 (ru) Антагонист минералокортикоидного рецептора и способы его применения
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
WO2015095097A3 (en) Inhibitors of the renal outer medullary potassium channel